GlassScriptPhysician profile
Julian Parent
NPI 1649165127
$1,206.56
in general payments reported to CMS, 2019-2025
34 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $94.91 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $78.63 | 2025 | |
| Incyte Corporation | $69.13 | 2025 | Monjuvi, Jakafi, Zynyz |
| Abbvie INC. | $52.08 | 2025 | |
| Genentech USA, INC. | $51.34 | 2025 | Venclexta, Tecentriq |
| Syndax Pharmaceuticals, INC. | $49.45 | 2025 | |
| Genzyme Corporation | $48.33 | 2025 | |
| Merck Sharp & Dohme LLC | $47.02 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $44.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $44.17 | 2025 | Imfinzi, Enhertu |
| Siemens Medical Solutions USA, INC. | $43.87 | 2025 | Truebeam |
| Karyopharm Therapeutics INC. | $34.88 | 2025 | Xpovio |
| Pharmaessentia USA Corporation | $34.78 | 2025 | Besremi |
| Tersera Therapeutics LLC | $31.23 | 2025 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.53 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $29.97 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $28.32 | 2025 | Romvimza, Qinlock |
| Amneal Pharmaceuticals LLC | $28.17 | 2025 | Pemrydi Rtu |
| Genmab U.S., INC. | $26.42 | 2025 | Epkinly |
| Coherus Oncology, INC. | $25.85 | 2025 | Loqtorzi |
| Daiichi Sankyo INC. | $24.79 | 2025 | Enhertu |
| Alnylam Pharmaceuticals INC. | $24.44 | 2025 | Givlaari |
| Rigel Pharmaceuticals, INC. | $23.71 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Eisai INC. | $23.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.37 | 2025 | |
| Sobi, INC | $22.80 | 2025 | |
| Celgene Corporation | $22.41 | 2025 | Reblozyl |
| Iovance Biotherapeutics, INC. | $22.38 | 2025 | Amtagvi |
| Servier Pharmaceuticals LLC | $22.34 | 2025 | |
| Puma Biotechnology, INC. | $22.26 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.74 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $21.69 | 2025 | |
| Lilly USA, LLC | $20.57 | 2025 | Jaypirca, Verzenio |
| Array Biopharma INC | $16.75 | 2025 | Mektovi, Xalkori, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Parent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.